GF
Therapeutic Areas
CAMP4 Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Undisclosed PRAM (SCN1A-targeting) | Dravet Syndrome | Preclinical |
| Undisclosed PRAM (CDKL5-targeting) | CDKL5 Deficiency Disorder | Preclinical |
| Undisclosed PRAM (OTC-targeting) | Ornithine Transcarbamylase (OTC) Deficiency | Preclinical |
Leadership Team at CAMP4 Therapeutics
JM
Joshua Mandel-Brehm, J.D.
President, Chief Executive Officer, and Board Member
MH
Michael H. Brodsky
Chief Scientific Officer and Board Observer
VS
Vivian S. Lee, M.D., Ph.D.
Chief Medical Officer
RA
Richard A. Young, Ph.D.
Scientific Co-Founder, Professor at MIT, Member of Whitehead Institute
DM
David M. Bartel, Ph.D.
Scientific Co-Founder, Professor at MIT, HHMI Investigator